Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has reported new data from two Phase III studies which showed that in patients with multiple lipid problems, the company's TriLipix combined with two commonly prescribed statins, significantly improved three key lipids, compared to the corresponding monotherapies.
Subscribe to our email newsletter
Both TriLipix (ABT-335) studies are part of the largest clinical program to date designed to evaluate the efficacy and safety of a fibrate in combination with statins. These studies using fenofibric acid combined with atorvastatin and simvastatin met their primary endpoints.
Combination therapy significantly improved high-density lipoproteins (HDL) and triglycerides compared to statin therapy alone, and significantly improved low-density lipoprotein (LDL) compared to TriLipix alone. Both the combinations and the two statins had clinically meaningful reductions in LDL. In the clinical trials, combination therapy was generally well tolerated, with reported safety similar to the monotherapies.
Christie Ballantyne, investigator in the TriLipix studies, said: “Data from these two studies show that TriLipix in combination with atorvastatin or simvastatin improved all three key lipids, LDL, HDL and triglycerides, in patients with multiple lipid problems.”